Data-Driven Disease Insights for Target Selection

With over 70% of failures in the clinical stage attributed to the choice of drug target, preclinical target selection is the most impactful step in drug development. We collaborate with biopharma companies to address this issue by establishing a data-driven, actionable target selection process that maximizes preclinical confidence in target efficacy and safety. 

We contribute to this in the following ways. We create biological knowledge graphs that harmonize public and proprietary data, making it available across the target selection process. Based on this, our computational disease models predict novel targets and provide insights in the underlying disease biology. We then empower biological researchers to assess these target predictions by developing structured target assessment workflows tailored to their specific evaluation criteria and therapeutic context. 

This enables biopharma companies to maximize confidence in preclinical target discovery, indication expansion and target assessment, lowering the risks and time frames of drug development. 

Euretos Offices


Euretos Europe

Visiting Address:

Utrecht Science Park, 

Yalelaan 1

3584 CL, Utrecht

Call: +31 30-2536886

KVK#: 77761596

VAT#: NL 861131824.B01


Euretos USA

Visiting Address:

One Beacon Street


MA 02108


Email: information [at]

General Terms and Conditions

These are the general terms and conditions which apply to the services Euretos provides and the access to the Euretos AI Platform. These may be changed from time to time.

General Terms and Conditions - Euretos AI Platform

Euretos Privacy Policy

General Terms and Conditions - Euretos Services

Enabling world leading pharma, biotech and academic institutions
Janssen and Janssen Pharmaceutical Companies
Leiden Academic Centre for Drug Research
Astra Zeneca
Boehringer Ingelheim